approach, detection of a small subclonal fraction of cells is difficult unless one incorporates single-cell analysis, which may not be practical for routine use. Thus, the p53 score will likely be best used in concert with current approaches to assess the prognostic impact and aid most accurately in treatment decisions.

Conflict-of-interest disclosure: The authors declare no competing financial interests. ■

REFERENCES

- Durand R, Descamps G, Bellanger C, et al. A p53 score derived from TP53 CRISPR/Cas9 HCMLs predicts survival and reveals a major role of BAX in response to BH3-mimetics. *Blood.* 2024;143(13):1242-1258.
- Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. *Front Immunol.* 2019;10:1121.
- Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood*. 2016; 127(24):2955-2962.
- Barwick BG, Neri P, Bahlis NJ, et al. Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. *Nat Commun.* 2019;10(1):1911.

LYMPHOID NEOPLASIA

Comment on Bomsztyk et al, page 1259

- Weinhold N, Ashby C, Rasche L, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. *Blood*. 2016;128(13):1735-1744.
- Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. *Leukemia*. 2019;33(1):159-170.
- Lin YHT, Way GP, Barwick BG, et al. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. *Blood Adv.* 2019;3(21):3214-3227.
- Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. *Nat Rev Clin Oncol.* 2018;15(1):13-30.
- Schmidt TM, Barwick BG, Joseph N, et al. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. *Blood Cancer J.* 2019;9(12):94.
- Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol. 2022;19(4):223-236.

https://doi.org/10.1182/blood.2023023487

© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, Al training, and similar technologies.

AL amyloidosis response: a move in the "light" direction

Angela Dispenzieri | Mayo Clinic

As redemonstrated by Bomsztyk et al¹ in this issue of *Blood*, top-down mass spectrometry (MS) of blood has been transformative for diagnosing and monitoring plasma cell disorders,²⁻⁷ and immunoglobulin light chain (AL) amyloidosis is no exception.^{3,8,9}

To date, every comparator study using a 5-bead MS-based assessment of hematologic response compared with standard immunofixation in either multiple myeloma or AL amyloidosis has favored the MS approach because of both improved sensitivity and specificity of the MS assays.⁵⁻⁹ Bomsztyk et al take this a step further in AL amyloidosis, which is a disease primarily of elevated free light chains (FLCs), by using an MS assay that detects FLCs (FLC-MS) rather than total light chains (those light chains bound to intact immunoglobulins plus FLCs [see figure panel A]).¹ The authors studied 487 patients who were newly diagnosed with AL amyloidosis who were treated with bortezomib-based regimens with serial measures. All but 4 had their FLC peak identifiable by FLC-MS. Using FLC-MS, they demonstrated that fewer patients had as deep a response as estimated by standard hematologic measures (ie, the International Society of Amyloidosis amyloid response criteria, which are dependent on immunofixation and the nephelometric FLC assay) (see figure panel B, panel 1). Overall, only 21% of patients were FLC-MS negative at 12 months, and the likelihood of being FLC-MS negative increased with superior hematologic response status (see figure panel B, panel 2). Notably, 12 months after diagnosis, 32% of their patients had been classified as amyloid complete hematologic response, but only 39% of these had a negative FLC-MS, making only 13% of the entire cohort both amyloid complete response and FLC-MS negative.

FLC-MS negativity translated into a higher likelihood of organ response at 12 months, with 70% and 38% of organ responseeligible patients having a cardiac and renal response, respectively. Overall survival was also better among patients who had a negative (compared with a positive) FLC-MS in each of the following patient populations: (1) all, regardless of standard hematologic response; (2) complete hematologic responders; and (3) very good partial responders (see figure panel C). Patients achieving complete hematologic response but who remained FLC-MS positive had similar overall survival compared with patients in very good partial response.

These results are exciting, but there are several limitations to this study. First, although there are 2 commercially available top-down MS assays (Mass-Fix and EXENT), the FLC-MS, the assay used in this study, is not currently commercially available (see figure panel A), making this article academically interesting, but not yet applicable for general practice. It would have been useful had they contextualized the FLC-MS results relative to the EXENT assay. How do the existing MS assays perform relative to the FLC-MS assay? Investigators from the Mayo Clinic compared the FLC-MS with the Mass-Fix assay in the sera of 167 patients (see figure panel D).¹⁰ Concordance between Mass-Fix and FLC-MS assays was 74%, with the vast majority of the discrepancy due to the greater sensitivity of the FLC-MS. When the results of the FLC ratio derived from the FLC nephelometric assay were combined with the Mass-Fix result, concordance between these 2 commercially available assays and the FLC-MS assay was 88%, with the discordance relating predominantly to abnormal FLC ratios (typically favoring κ) in the setting of a negative FLC-MS. The ability of this combination rivaled the FLC-MS for detecting λ clones. Extrapolation to the



(A) Representation of the MS assays, highlighting their differences. (B) Interaction of FLC-MS response at 12 months with standard amyloid hematologic response. N represents the total sample size from which the bar chart percent is calculated. Based on the study by Bomsztyk et al.¹ (C) Interaction of FLC-MS response with standard amyloid hematologic response at 12 months, and 5-year overall survival among patients. Based on data from the study by Bomsztyk et al.¹ (D) Relative performance of FLC-MS, Mass-Fix, and Mass-Fix plus nephelometric FLC ratio. Note the single Mass-Fix κ adjudicated as λ was actually a biclonal IgG κ plus free λ . Based on data from the study by Sepiashvili et al.¹⁰ CR, complete hematologic response; ISA, International Society of Amyloidosis; MALDI, matrix-assisted laser desorption/ionization; NA, not available; neg, negative; OS, overall survival; pos, positive; PR, partial response; VGPR, very good partial response.

present study is imperfect because the Mayo study was not done specifically in a population with AL amyloidosis. Bomsztyk et al reported on limited comparisons of the nephelometric FLC assay, immunofixation, and the FLC-MS. For example, they demonstrated that among those patients with AL in very good partial response who were also FLC-MS negative, of the discordant cases, approximately two-thirds were due to a positive immunofixation and approximately two-thirds to the difference between κ and λ FLC (dFLC) of >10 mg/L. Although one would expect that the FLC-MS would be more specific than

the nephelometric FLC method, which largely relies on ratios—and the multivariate analyses in part bore out this prospect—the analyses would have been even more persuasive had hematologic complete response and good partial response been adjudicated using the commercially available MS assays rather than immunofixation, the latter of which has been well established to be less sensitive and less specific than the existing MS assays.²⁻⁸

The second major limitation of this study is no bone marrow data were provided such that the comparison between bone marrow minimal residual disease and FLC-MS could be made. Using the commercial assays that detect total light chains (rather than free light chains), there is a growing body of literative of how valuable the EXENT and the Mass-Fix assays can be in detecting bone marrow minimal residual disease among patients with AL amyloidosis^{8,9} as well as multiple myeloma.⁴⁻⁷

In short, this work provides exciting data on a yet to be approved assay. Monitoring hematologic response has come a long way in AL amyloidosis: from barely detectable monoclonal proteins by serum protein electrophoresis and immunofixation to nephelometric serum FLCs to total light chain-based MS assays and hopefully soon to FLC-MS assays. Until FLC-MS is commercially available, we will rely on the next best, which is total light chain-based MS and the nephelometric FLC assays of the blood (see figure panel D).

Conflict-of-interest disclosure: A.D. reports being on the advisory board and independent review committee of Janssen; being on the data monitoring safety committees of Oncopeptides and Sorrento; and receiving research funding from Alnylam, Pfizer, Takeda, and Bristol Myers Squibb.

REFERENCES

- Bomsztyk J, Ravichandran S, Giles HV, et al. Complete responses in AL amyloidosis are unequal – the impact of free light chain mass spectrometry in AL amyloidosis. *Blood*. 2024; 143(13):1259-1268.
- Mills JR, Barnidge DR, Murray DL. Detecting monoclonal immunoglobulins in human serum using mass spectrometry. *Methods*. 2015;81:56-65.
- Milani P, Murray DL, Barnidge DR, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. *Am J Hematol.* 2017;92(8):772-779.
- Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. *Blood Cancer J.* 2021;11(2):24.
- Derman BA, Stefka AT, Jiang K, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. *Blood Cancer J.* 2021;11(2):19.
- Puig N, Contreras MT, Agullo C, et al. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. *Blood Adv.* 2022;6(11):3234-3239.
- Dispenzieri A, Krishnan A, Arendt B, et al. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). *Blood Cancer J.* 2022;12(2):27.
- Dispenzieri A, Arendt B, Dasari S, et al. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. *Blood Cancer J*. 2020;10(2):20.
- Sharpley FA, Manwani R, Mahmood S, et al. A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis. *Blood Cancer J.* 2019;9(2):16.

 Sepiashvili L, Kohlhagen MC, Snyder MR, et al. Direct detection of monoclonal free light chains in serum by use of immunoenrichmentcoupled MALDI-TOF mass spectrometry. *Clin Chem.* 2019;65(8):1015-1022.

MYELOID NEOPLASIA

Comment on Mathioudaki et al, page 1269

GPR56 in GVL: marker or mechanism?

Audra N. Iness^{1,2} and Pavan Bachireddy² | ¹Baylor College of Medicine and ²MD Anderson Cancer Center

In the current issue of *Blood*, Mathioudaki et al¹ use single-cell RNA sequencing to identify adhesion G-protein coupled receptor GPR56 as a marker of an antigen-experienced, antileukemic CD8⁺ T-cell subset that is associated with complete remission (CR) after allogeneic stem cell transplant (alloSCT) for acute myeloid leukemia (AML). By coupling in silico, high-throughput discovery technologies with immunophenotyping and in vitro cytotoxicity assays, the authors lay the groundwork for prospective investigation of GPR56 as a clinically predictive marker of post-SCT outcomes.

The graft-vs-leukemia (GVL) effect is widely recognized as the major determinant of alloSCT therapeutic efficacy for high-risk hematologic malignancies. Mechanistically, GVL is driven largely by donor T cells eliminating recipient leukemic cells. However, this antitumor alloreactivity must be highly specific and thus modulated by immunosuppressive agents to protect against graft-versus-host disease (GVHD). Post-SCT relapse is therefore chiefly attributed to failure of GVL, and identifying the responsible molecular pathways could illuminate novel therapeutic strategies to maximize GVL without increasing GVHD. Recent technological developments have enabled high-resolution inspection of the GVL effect, unveiling several complex cellular processes and new avenues for clinical exploration. Studies focused on malignant cells have documented loss of major histocompatibility complex expression, upregulation of immune-checkpoint ligands, secretion of inhibitory cytokines, and increased production of immunosuppressive enzymes as mechanisms for evading GVL.² For immunotherapies that reinstate the GVL effect, T cell-derived determinants of outcome have been identified, such as expansion of precursor exhausted T cells after donor lymphocyte infusion and increased infiltration of cytotoxic CD8⁺ T cells after checkpoint blockade.³⁻⁵

Here, the authors sought to understand the T cell-derived determinants of "endogenous" GVL in the early post-SCT period when the use of immunosuppressive GVHD prophylaxis is common. The authors generated single-cell transcriptomes on both marrow-infiltrating, CD34⁺ progenitors and CD3⁺ T cells collected 100 days after allo-SCT from patients with AML, to identify T-cell signatures associated with remaining in CR versus those found before imminent relapse (REL). Consistent with prior reports of an immunosuppressive phenotype and overall T-cell dysregulation in the REL state, the authors found enrichment of FOS/JUN, REL (NF-κB signaling pathway), CREM, and NFE2L2/NRF2 in the REL group.^{6,7} Likewise, differential expression analyses in CD8⁺ T cells revealed multiple genes in patients in CR linked to effector-memory function, including the TBX21 transcription factor regulon, targeting cytotoxic genes GZMB and KLRG1.⁸ Interestingly, among these differentially expressed genes was ADGRG1, encoding GPR56, a G-proteincoupled receptor and surface marker. GPR56 was previously associated with stemness and self-renewal phenotypes in AML as well as effector functions in T cells; however, the present study is the first to associate it with GVL (see figure).^{9,10}

https://doi.org/10.1182/blood.2023023393

© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, Al training, and similar technologies.